Cargando…
OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065936/ http://dx.doi.org/10.1016/S1590-8658(22)00327-9 |
| _version_ | 1784699698100043776 |
|---|---|
| author | Pisani, L.F. Mola, S. Crespi, G. Caprioli, F. Annunaziata, M. Manfredi, M. Pastorelli, L. Porta, C. |
| author_facet | Pisani, L.F. Mola, S. Crespi, G. Caprioli, F. Annunaziata, M. Manfredi, M. Pastorelli, L. Porta, C. |
| author_sort | Pisani, L.F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9065936 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90659362022-05-04 OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION Pisani, L.F. Mola, S. Crespi, G. Caprioli, F. Annunaziata, M. Manfredi, M. Pastorelli, L. Porta, C. Dig Liver Dis Oral Communications Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2022-05 2022-05-04 /pmc/articles/PMC9065936/ http://dx.doi.org/10.1016/S1590-8658(22)00327-9 Text en © 2022 Editrice Gastroenterologica Italiana S.r.l. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Oral Communications Pisani, L.F. Mola, S. Crespi, G. Caprioli, F. Annunaziata, M. Manfredi, M. Pastorelli, L. Porta, C. OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION |
| title | OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION |
| title_full | OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION |
| title_fullStr | OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION |
| title_full_unstemmed | OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION |
| title_short | OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION |
| title_sort | oc.10.2 a serum metabolomics analysis to understand the interplay between biological therapies in ibd patients and susceptibility to sars-cov-2 infection |
| topic | Oral Communications |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065936/ http://dx.doi.org/10.1016/S1590-8658(22)00327-9 |
| work_keys_str_mv | AT pisanilf oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection AT molas oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection AT crespig oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection AT capriolif oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection AT annunaziatam oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection AT manfredim oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection AT pastorellil oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection AT portac oc102aserummetabolomicsanalysistounderstandtheinterplaybetweenbiologicaltherapiesinibdpatientsandsusceptibilitytosarscov2infection |